Market Size of Adeno-Associated Virus (AAV) CDMO Industry
| Study Period | 2021 - 2029 |
| Market Size (2024) | USD 0.57 Billion |
| Market Size (2029) | USD 1.40 Billion |
| CAGR (2024 - 2029) | 20.86 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Adeno-Associated Virus (AAV) CDMO Market Analysis
The Adeno-Associated Virus CDMO Market size is estimated at USD 0.57 billion in 2024, and is expected to reach USD 1.40 billion by 2029, growing at a CAGR of 20.86% during the forecast period (2024-2029).
The key factors driving the growth of the adeno-associated virus CDMO market include the increasing use of gene therapy, advancements in AAV vectors, and rising outsourcing of AAV vector manufacturing.
Companies operating in the AAV development field are developing new technologies and engaging in strategic activities that benefit the market. For instance, in November 2022, Thermo Fisher Scientific introduced the Gibco CTS adeno-associated virus (AAV) MAX Helper Free production system, which it claims can save time and reduce costs by 50%. The CTS AAV-MAX system includes several components: mammalian cells, a cell culture medium, a transfection kit, and a buffer.
In February 2022, Mirus Bio launched Transit-VirusGEN SELECT Transfection Kits for large-scale viral vector production for cell and gene therapy applications. The kits support pre-clinical and process development activities and consist of the TransIT-VirusGEN Transfection Reagent, a complex formation solution, and an enhancer. Hence, the introduction of AAV technologies is expected to increase its demand, and production is likely to boost the demand for CDMO services over the forecast period.
Furthermore, growing research identifying the importance of gene therapy in treating life-threatening diseases is propelling market growth. For instance, the study published in the Radiology and Oncology Journal in February 2022 claimed that the use of adeno-associated viral vectors to treat cancer had the potential to change the area of oncology. Virus vectors, in particular, provide a unique mix of effective gene delivery and immune system engagement for anti-tumour responses. Such studies are expected to increase the adoption of AAV contract manufacturing in designing cancer therapies, driving market growth.
However, production capacity challenges and regulatory issues are expected to hinder market growth in the long run.
Adeno-Associated Virus (AAV) CDMO Industry Segmentation
As per the scope of the report, AAV is a protein shell surrounding and protecting a small, single-stranded DNA genome. AAV CDMO refers to the contract manufacturing organizations that are involved in the development of AAV.
The AAV CDMO market is segmented by workflow, culture type, application, end user, and geography. By workflow, the market is segmented into upstream processing and downstream processing. By culture type, the market is segmented into adherent culture and suspension culture. By application, the market is segmented into cell & gene therapy development, vaccine development, biopharmaceutical & pharmaceutical discovery, and biomedical research. By end user, the market is segmented into pharmaceutical & biopharmaceutical companies and academic & research institutes. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD) for all the above segments.
| By Workflow | |
| Upstream Processing | |
| Downstream Processing |
| By Culture Type | |
| Adherent Culture | |
| Suspension Culture |
| By Application | |
| Cell & Gene Therapy Development | |
| Vaccine Development | |
| Biopharmaceutical & Pharmaceutical Discovery | |
| Biomedical Research |
| By End User | |
| Pharmaceutical & Biopharmaceutical Companies | |
| Academic & Research Institutes |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Adeno-Associated Virus (AAV) CDMO Market Size Summary
The Adeno-Associated Virus (AAV) CDMO market is poised for significant growth, driven by the increasing application of gene therapy and advancements in AAV vector technologies. The market is experiencing a surge in demand due to the rising outsourcing of AAV vector manufacturing, which is further bolstered by strategic innovations and collaborations among key industry players. Companies like Thermo Fisher Scientific and Mirus Bio are introducing advanced production systems and transfection kits, respectively, to enhance efficiency and reduce costs in viral vector production. These technological advancements are expected to propel the demand for CDMO services, particularly in the context of developing therapies for life-threatening diseases such as cancer. The integration of AAV vectors in oncology is gaining traction, with research highlighting their potential in transforming cancer treatment, thereby driving the adoption of AAV contract manufacturing.
North America is anticipated to lead the AAV CDMO market, supported by a robust pharmaceutical and biotechnology sector and a growing emphasis on contract manufacturing. The region's market growth is further fueled by substantial investments in gene therapy research and development, as evidenced by significant funding from both private companies and government initiatives. The competitive landscape of the market is characterized by strategic collaborations, mergers, and acquisitions among key players like Thermo Fischer Scientific, Creative Biogene, and Catalent Inc. These companies are focusing on expanding their capabilities and enhancing their service offerings to maintain a competitive edge. Despite challenges such as production capacity and regulatory issues, the market is expected to continue its upward trajectory, driven by the burgeoning cell and gene therapy segment and the increasing adoption of precision medicine approaches.
Adeno-Associated Virus (AAV) CDMO Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Adeno-Associated Virus (AAV) Pipeline: Promising Gene Therapy and Vaccine Prospects
-
1.2.2 Advancements in Adeno-Associated Viral Vector Manufacturing
-
1.2.3 Rising Outsourcing of AAV Vector Manufacturing and Intense Competition and Diverse Strategies in the Market
-
-
1.3 Market Restraints
-
1.3.1 Regulatory, Scientific, and Ethical Challenges Associated with Gene Therapy and Viral Vectors
-
1.3.2 Manufacturing Challenges in Producing AAV Viral Vectors
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size - Value in USD)
-
2.1 By Workflow
-
2.1.1 Upstream Processing
-
2.1.2 Downstream Processing
-
-
2.2 By Culture Type
-
2.2.1 Adherent Culture
-
2.2.2 Suspension Culture
-
-
2.3 By Application
-
2.3.1 Cell & Gene Therapy Development
-
2.3.2 Vaccine Development
-
2.3.3 Biopharmaceutical & Pharmaceutical Discovery
-
2.3.4 Biomedical Research
-
-
2.4 By End User
-
2.4.1 Pharmaceutical & Biopharmaceutical Companies
-
2.4.2 Academic & Research Institutes
-
-
2.5 Geography
-
2.5.1 North America
-
2.5.1.1 United States
-
2.5.1.2 Canada
-
2.5.1.3 Mexico
-
-
2.5.2 Europe
-
2.5.2.1 Germany
-
2.5.2.2 United Kingdom
-
2.5.2.3 France
-
2.5.2.4 Italy
-
2.5.2.5 Spain
-
2.5.2.6 Rest of Europe
-
-
2.5.3 Asia-Pacific
-
2.5.3.1 China
-
2.5.3.2 Japan
-
2.5.3.3 India
-
2.5.3.4 Australia
-
2.5.3.5 South Korea
-
2.5.3.6 Rest of Asia-Pacific
-
-
2.5.4 Middle East and Africa
-
2.5.4.1 GCC
-
2.5.4.2 South Africa
-
2.5.4.3 Rest of Middle East and Africa
-
-
2.5.5 South America
-
2.5.5.1 Brazil
-
2.5.5.2 Argentina
-
2.5.5.3 Rest of South America
-
-
-
Adeno-Associated Virus (AAV) CDMO Market Size FAQs
How big is the Adeno-Associated Virus CDMO Market?
The Adeno-Associated Virus CDMO Market size is expected to reach USD 0.57 billion in 2024 and grow at a CAGR of 20.86% to reach USD 1.40 billion by 2029.
What is the current Adeno-Associated Virus CDMO Market size?
In 2024, the Adeno-Associated Virus CDMO Market size is expected to reach USD 0.57 billion.
